Voriconazole pharmacokinetics and pharmacodynamics in children. - Wikidata - awgldk - TriplyDB

Voriconazole pharmacokinetics and pharmacodynamics in children.

Voriconazole pharmacokinetics and pharmacodynamics in children.

http://www.wikidata.org/entity/Q33577291

about

Treatment and prophylaxis of invasive candidiasis Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Voriconazole monitoring in children with invasive fungal infections Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Achieving target voriconazole concentrations more accurately in children and adolescents.Population pharmacokinetics of voriconazole in adults Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.Pharmacokinetics of antifungal agents in children.Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.Software for dosage individualization of voriconazole for immunocompromised patients Plasma Voriconazole Estimation by HPLC.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies Therapeutic drug monitoring in voriconazole-associated hyponatremia.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.Comparison of clinical pharmacology of voriconazole and posaconazole.Pharmacoeconomics of voriconazole in the management of invasive fungal infections.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

P2860

Q27001567-A85528CC-34D1-46AD-9642-9FC6155FE16C Q27009221-EF95E0BA-C4D5-474F-92B0-8D59CD077781 Q27025299-63B355D2-6F07-42E5-ACD3-568A96B69881 Q33559503-141258E8-2882-4583-96F1-5BB4814A107E Q33681237-DC1C458E-4EC2-4287-8097-A4F5C12363B2 Q33827819-2EF38C85-CB0C-4086-8892-2CA06E06F3E6 Q33849298-2AD8FC32-0AE4-45AD-8F5D-C7BD605D20AE Q34020402-81360287-628B-4B80-9D50-E6779D3EFE41 Q34045383-7070BCFD-D0E4-4A4A-A3CD-B3734EC7DE96 Q34138276-4CEE449C-21AF-4EAA-AB47-67ED180D805A Q34150923-9310ACFC-7ABF-44B3-858E-D90A6DC68853 Q34150943-80824282-0A1A-4312-9345-107A86E5B825 Q34505582-908E7A6E-E93E-4241-9ACB-0DF1249089A1 Q35105949-0AD62DD4-BC36-4158-A972-C0D9116B3978 Q35157940-1FBB3DF2-D0D2-4A17-BEF7-D3B90445E80A Q35169112-7D642953-5C72-49C3-A761-B8AB51FB123C Q35270270-54CD98DF-5663-4B58-99CA-D37C58DC9056 Q35598464-31790E92-C7BF-4370-9E25-66641B10D82A Q35598532-6075D523-A609-43C5-9AB2-D4C9C280BCCC Q35607652-A68D8767-5DBD-4FFE-97FA-DE3ECD921917 Q35666490-B2226494-9D92-4307-B12E-B05E9BF93127 Q35973543-A95E0C6C-4CB7-426E-9D66-4FF6E4BC1F2C Q36163345-99EFAED0-4228-4B3C-A3FA-34B6E547FB3C Q36172497-553275BB-EAAA-4DC1-BF8D-BE4EA1EFBAFE Q36273788-D5AAC10D-8972-4AC5-8F64-37DD70444EFC Q36505462-B637A7E3-B9DE-4D6A-91A4-6D6063221A48 Q36521993-D6508919-203F-44FA-8EA2-EE38E826CA9C Q36608562-72F9D4D9-22ED-4482-944D-6C2FD6F948F3 Q36730105-309FD434-3D8A-4018-8E97-FA69031C2DE6 Q36757595-7CFF8D10-B861-4FD6-B828-A3DE8B3B63F4 Q36764126-3C56E226-E59A-481C-ABFB-D8D6710F3469 Q36927577-97EF9854-D707-4013-8D05-69D9D17536E5 Q36948094-8BCD934F-33E5-4CA7-872C-D3496D56BF3C Q36969780-09DC70A5-EBC9-4230-B442-B427009999D1 Q37454178-6946A657-1EF2-4202-AF53-47A1BB02863E Q37688257-55DD0B92-A4DB-41A7-A4F7-AAE9234D041A Q37693296-C41000CF-0404-4058-9611-63564DC994B3 Q37727651-14CFC5A1-4602-4B84-98BF-1B2D71A44E4C Q37820674-5E98B27E-CED5-41E5-AB2C-4FD369D2B495 Q37835819-317CE197-535D-4063-94C1-042BCE3CE89F

P2860

Voriconazole pharmacokinetics and pharmacodynamics in children.

http://www.wikidata.org/entity/Q33577291

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Voriconazole pharmacokinetics and pharmacodynamics in children.

@ast

Voriconazole pharmacokinetics and pharmacodynamics in children.

@en

Voriconazole pharmacokinetics and pharmacodynamics in children.

@nl

type

label

Voriconazole pharmacokinetics and pharmacodynamics in children.

@ast

Voriconazole pharmacokinetics and pharmacodynamics in children.

@en

Voriconazole pharmacokinetics and pharmacodynamics in children.

@nl

prefLabel

Voriconazole pharmacokinetics and pharmacodynamics in children.

@ast

Voriconazole pharmacokinetics and pharmacodynamics in children.

@en

Voriconazole pharmacokinetics and pharmacodynamics in children.

@nl

P1433

Q33577291-5379EF0A-DF20-4FEF-9C8F-D3478A7F6808

P1476

Q33577291-B45CB32A-9905-4F37-A1E5-B81E1E8BD13A

P2093

Q33577291-008E479D-A629-4B32-B6E4-7386D407F1FD

Q33577291-29275D03-41C6-46FE-9578-4E2A6E1BE7A0

Q33577291-46A1D158-0FF9-465D-AEE9-4988BB0BBF0B

Q33577291-9386E2E9-E2AC-4229-B3DD-F0B2C4477570

Q33577291-B21414F6-38B0-4F79-A874-0A5AE274E846

P2860

Q33577291-0D9AC0EB-9E0D-4015-BBC5-038D4D820E5B

Q33577291-0E8F01F3-EAEF-4B66-A413-2D6E5430D54B

Q33577291-1E136888-E814-40C0-98C9-C162480B1806

Q33577291-30665A5F-66BE-4618-9ED0-1395BB67D08C

Q33577291-46BE6AE4-9DC3-4148-98F6-4063FBD84A27

Q33577291-5B69A673-2583-443E-B0BE-523F62B5F555

Q33577291-5D0F36AE-91CD-46DB-AE32-D43D59058068

Q33577291-6114FA9E-F852-4713-AC86-0F3A3374F7B4

Q33577291-66518E07-64BE-429F-B845-0503F2460D7A

Q33577291-8E4CBAD7-FE93-404B-99E5-0AFE7FBE99EA

P304

Q33577291-44B52CF8-5C96-4EBF-81C7-AFF65B1FFDB1

P31

Q33577291-0DF8B2BE-C437-4683-8B92-8C78B1C2932F

P356

Q33577291-4D296D94-A710-4021-9F68-E4A234B04FB5

P407

Q33577291-EB169C10-4924-4992-A0FB-1F34A034FDAA

P433

Q33577291-8249BD27-B16A-4C49-A393-19E89F58AD96

P478

Q33577291-1639696C-4184-45B5-80F5-E67096CB636F

P577

Q33577291-3651955E-2258-41F4-B7A5-D2C3E045AE90

P5875

Q33577291-1285B079-68EF-4B1B-957B-3E9C5EB094E1

P698

Q33577291-2C010339-6A7D-4F49-9D5D-19F9D08EB5A3

P932

Q33577291-703CF254-E241-408C-95BD-F1CF6DECF9A7

P356

P1433

Clinical Infectious Diseases

P1476

Voriconazole pharmacokinetics and pharmacodynamics in children.

@en

P2093

Andrea Kovacs

http://www.w3.org/2001/XMLSchema#string

Jill Hoffman

http://www.w3.org/2001/XMLSchema#string

Michael Neely

http://www.w3.org/2001/XMLSchema#string

Roger Jelliffe

http://www.w3.org/2001/XMLSchema#string

Teresa Rushing

http://www.w3.org/2001/XMLSchema#string

P2860

Severe osteomyelitis caused by Myceliophthora thermophila after a pitchfork injury

Voriconazole therapeutic drug monitoring.

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Antifungal serum concentration monitoring: an update.

Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

P304

27-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/648679

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40044211

http://www.w3.org/2001/XMLSchema#string

P698

19951112

http://www.w3.org/2001/XMLSchema#string

P932

2803104

http://www.w3.org/2001/XMLSchema#string